# Cervical Cancer Prevention for NEET PG OBG: HPV, CIN, VIA Screening, India's 2026 HPV Vaccination Campaign and Cervical Cancer Staging

Source: https://tracknation.in/story/cervical-cancer-prevention-for-neet-pg-obg-hpv-cin-via-screening-india-s-2026-hpv-vaccination-campaign-and-cervical-cancer-staging (TrackNation — free UPSC notes with PYQs)

> NEET PG Gynaecology: HPV causation and types, CIN grades and LSIL/HSIL, transformation zone, India's VIA screening under NP-NCD, US Pap/HPV schedules, India's February 2026 HPV campaign (Gardasil quadrivalent, single dose, girls aged 14, U-WIN), WHO 90-70-90, cervical cancer symptoms, FIGO 2018 stages and treatment, with a diagram, hooks, vignette MCQs and cards.

## Start Here

🎯 **Exam priority: Very high.** *Expect: HPV types and attributable fractions, India's 2026 campaign details (vaccine, dose, age,
consent), WHO 90-70-90, VIA screening under NP-NCD and what happens to VIA-positive women, CIN grades and Bethesda terms, first symptom of cancer,
FIGO stage clues and treatment by stage.*

CBME mapping: **OG33**. Indian anchors: MoHFW HPV Vaccination Campaign Operational Guidelines (February 2026) and NP-NCD Operational
Guidelines (2023).

*HPV, India's vaccine campaign, VIA screening and cervical cancer staging. Drawn by TrackNation.*

## HPV and Precancer (MoHFW 2026, MSD)

- **99.7%** of cervical cancers come from **persistent high-risk HPV**; HPV is the commonest viral reproductive-tract infection.
**HPV 16 + 18** cause **77%** of cases worldwide and **83% in India**. Among Indian women, cervical cancer is second only to
breast cancer (NP-NCD).

- Cancers arise in the **transformation zone** (squamous metaplasia around the external os); most are **squamous cell
carcinomas**, fewer adenocarcinomas.

- **CIN 1** mild, **CIN 2** moderate, **CIN 3** severe dysplasia/carcinoma in situ (rarely regresses). Bethesda: **LSIL =
HPV/CIN 1**; **HSIL = CIN 2–3**; also ASC-US, ASC-H.

- ICMR: hysterectomy may be considered for **CIN II with poor compliance or CIN III** (family complete).

## Screening (NP-NCD 2023, MSD)

- **India (NP-NCD)**: population-based screening of people **30 years and above** for hypertension, diabetes and cancers of
the **oral cavity, cervix and breast**. **VIA (visual inspection with acetic acid)** is done by a trained staff nurse/MO at the
**PHC-HWC**.

- **VIA-positive** women are referred to higher facilities for **colposcopy and/or cryotherapy**.

- MSD (US) schedules for comparison: start at 21–25; **Pap every 3 years** at 21–29; **HPV test or co-test every 5 years** to 65;
stop after 65 if previous tests over 10 years were normal. VIA or Lugol iodine is the alternative where Pap/HPV tests are unavailable.

- **WHO 2030 targets (90-70-90)**: 90% of girls vaccinated by 15; 70% of women screened with a high-performance test by 35 and again
by 45; 90% of women with disease treated. Elimination threshold: **4 per 1,00,000 women-years**.

## India's HPV Vaccination Campaign (MoHFW, February 2026)

- Vaccine: **Gardasil — quadrivalent (types 6, 11, 16, 18)**; stored at **+2 to +8 °C, freeze-sensitive**. (DCGI-licensed in
India: Cervarix, Gardasil, Gardasil-9, Cervavac.)

- Target: **girls who have had their 14th birthday but not their 15th** (~1.2 crore a year); after the 3-month campaign the vaccine is
on routine immunisation days for 14-year-old girls.

- Schedule: **single dose** — an off-label schedule recommended by **WHO and NTAGI**; IM in the deltoid. (WHO: 2 doses ≥6
months apart is the licensed schedule; single dose usable at 9–20 years.)

- **Voluntary**; **parent/guardian consent is mandatory**, recorded on **U-WIN**. Not recommended in **pregnancy**
(no termination needed if given inadvertently); **breastfeeding is not a contraindication**. History: NTAGI recommended in 2017 and 2022;
Punjab pilot in 2016.

## Cervical Cancer (MSD)

- First symptom: **irregular, often postcoital, bleeding**; diagnosis by Pap test and **biopsy**.

- **FIGO 2018** staging allows imaging and pathology. Key clues: **IIB** parametrium (not to pelvic wall); **IIIB** pelvic
wall or **hydronephrosis/non-functioning kidney**; **IIIC** pelvic or para-aortic nodes.

- Treatment: **IA1 (no LVSI) → conisation or simple hysterectomy**; early stages → **surgery** (radical hysterectomy);
**locally advanced → chemoradiation**; metastatic → chemotherapy.

## Traps the Examiner Sets

- India's campaign: one dose, girls aged 14, quadrivalent Gardasil.

- Indian screening is VIA from age 30; Pap from 21 is the US schedule.

- Hydronephrosis puts cervical cancer in stage III regardless of size.

- HPV vaccine is not given in pregnancy but is fine during breastfeeding.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **India HPV campaign '1-4-14': 1 dose, quadrivalent (4 types), girls of 14** — campaign

- 🧠 **'16 and 18 = 83' in India** — HPV types

- 🧠 **WHO '90-70-90 by 2030' and elimination below 4 per lakh** — targets

- 🧠 **Screening: 'India VIA at 30; US Pap at 21'** — screening

- 🧠 **'Kidney blocked = stage 3' — hydronephrosis means IIIB** — staging

## Rapid-Revision Cards

- 99.7% of cervical cancers.

- 83% India; 77% global.

- 2nd after breast.

- Transformation zone.

- Mostly squamous.

- Severe dysplasia/CIS.

- CIN1 / CIN2–3.

- VIA, 30+, PHC-HWC.

- Colposcopy ± cryotherapy.

- Pap 3-yearly 21–29; HPV 5-yearly.

- Vaccinate, screen, treat by 2030.

- <4/100,000 women-years.

- Gardasil quadrivalent.

- Girls aged 14.

- Single (WHO/NTAGI).

- Parent/guardian on U-WIN.

- +2 to +8 °C; no freezing.

- Not given; no MTP if given.

- Postcoital bleeding.

- Stage IIIB.

- Chemoradiation.

## Sources

*Facts in this article were checked against these documents.*

- Operational Guidelines for Roll Out of HPV Vaccination Campaign — Ministry of Health & Family Welfare (Immunization Division), 2026

- Operational Guidelines: National Programme for Prevention and Control of Non-Communicable Diseases (2023–2030) — Ministry of Health & Family Welfare, 2023

- MSD Manual Professional: Cervical Cancer; Cervical Cancer Screening and Prevention — Merck & Co. (MSD Manuals), 2023–26 (link)

- Standard Treatment Workflow: Hysterectomy for Benign Gynaecological Conditions — Indian Council of Medical Research / DHR, 2025

- Competency Based Undergraduate Curriculum, Vol III: Obstetrics & Gynaecology (OG33) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** Persistent high-risk HPV infection causes about what share of cervical cancers?

- (a) 50%

- (b) 70%

- (c) 25%

- (d) 99.7%

**Answer: (d)** — MoHFW 2026.

**Q2.** HPV 16 and 18 account for what share of cervical cancer in India?

- (a) 99%

- (b) 30%

- (c) 83%

- (d) 50%

**Answer: (c)** — 77% globally.

**Q3.** Among Indian women, cervical cancer ranks

- (a) fifth

- (b) second, after breast cancer

- (c) first

- (d) below ovarian cancer

**Answer: (b)** — NP-NCD.

**Q4.** Most cervical cancers arise in the

- (a) transformation zone

- (b) parametrium

- (c) endometrium

- (d) upper endocervical canal only

**Answer: (a)** — Squamous metaplasia.

**Q5.** The commonest histological type of cervical cancer is

- (a) small cell carcinoma

- (b) squamous cell carcinoma

- (c) adenocarcinoma

- (d) sarcoma

**Answer: (b)** — MSD.

**Q6.** CIN 3 corresponds to

- (a) invasive cancer

- (b) normal cervix

- (c) severe dysplasia and carcinoma in situ

- (d) mild dysplasia

**Answer: (c)** — Rarely regresses.

**Q7.** In the Bethesda system, HSIL includes

- (a) CIN 2 and CIN 3

- (b) invasive cancer only

- (c) HPV infection only

- (d) CIN 1 only

**Answer: (a)** — LSIL = CIN 1.

**Q8.** Under NP-NCD, cervical cancer screening in India is done for women aged

- (a) 50 years and above

- (b) 21 years and above

- (c) 30 years and above

- (d) 15–25 years

**Answer: (c)** — Population-based.

**Q9.** The cervical screening test used at PHC-HWC level under NP-NCD is

- (a) liquid-based cytology

- (b) colposcopy

- (c) VIA (visual inspection with acetic acid)

- (d) HPV DNA PCR

**Answer: (c)** — Trained SN/MO.

**Q10.** A 36-year-old's VIA at the PHC-HWC is positive. Next per NP-NCD:

- (a) hysterectomy at PHC

- (b) repeat VIA in 10 years

- (c) reassure

- (d) refer for colposcopy and/or cryotherapy

**Answer: (d)** — Higher facility.

**Q11.** In the US schedule (MSD), women aged 21–29 are screened by

- (a) HPV test yearly

- (b) VIA every year

- (c) no screening

- (d) Pap test every 3 years

**Answer: (d)** — Then 5-yearly HPV/co-test.

**Q12.** Per MSD, screening can stop after 65 if

- (a) never

- (b) she has had 2 children

- (c) previous tests over the last 10 years were adequately normal

- (d) she is sexually inactive for 1 year

**Answer: (c)** — MSD.

**Q13.** The WHO 90-70-90 target includes

- (a) 90% of women screened by 25

- (b) 70% of girls vaccinated by 9

- (c) 90% cure of invasive cancer

- (d) 90% of girls fully vaccinated by age 15

**Answer: (d)** — By 2030.

**Q14.** Cervical cancer elimination as a public health problem (WHO) means incidence below

- (a) 40 per 100,000

- (b) 10 per 100,000

- (c) 1 per 1,000

- (d) 4 per 100,000 women-years

**Answer: (d)** — MoHFW 2026.

**Q15.** India's 2026 HPV campaign uses

- (a) nonavalent Gardasil-9

- (b) Cecolin

- (c) bivalent Cervarix

- (d) quadrivalent Gardasil (types 6, 11, 16, 18)

**Answer: (d)** — MoHFW.

**Q16.** The target group of India's 2026 HPV campaign is

- (a) girls who have turned 14 but not yet 15

- (b) boys and girls aged 18

- (c) women aged 30–49

- (d) girls aged 9–10

**Answer: (a)** — ~1.2 crore a year.

**Q17.** The dosing schedule in India's HPV campaign is

- (a) yearly boosters

- (b) two doses 6 months apart

- (c) a single dose (off-label, recommended by WHO and NTAGI)

- (d) three doses at 0, 2, 6 months

**Answer: (c)** — MoHFW.

**Q18.** Before vaccinating a 14-year-old girl in the campaign, you must have

- (a) a Pap smear

- (b) a pregnancy test

- (c) an HPV DNA test

- (d) parent/guardian consent, recorded on U-WIN

**Answer: (d)** — Voluntary.

**Q19.** HPV vaccine vials must be stored at

- (a) +2 to +8 °C and not frozen

- (b) +15 to +25 °C

- (c) room temperature

- (d) −20 °C

**Answer: (a)** — Freeze-sensitive.

**Q20.** A girl is found pregnant after receiving HPV vaccine. Management:

- (a) terminate the pregnancy

- (b) no termination needed; delay further doses until after pregnancy

- (c) start antivirals

- (d) give a booster immediately

**Answer: (b)** — MoHFW.

**Q21.** A breastfeeding 19-year-old asks for HPV vaccination. Breastfeeding is

- (a) an absolute contraindication

- (b) a reason to stop breastfeeding

- (c) not a contraindication

- (d) a reason for half dose

**Answer: (c)** — MoHFW.

**Q22.** The WHO primary target for HPV vaccination is

- (a) boys aged 15–18

- (b) pregnant women

- (c) girls aged 9–14 years, before sexual debut

- (d) women aged 30–49

**Answer: (c)** — MoHFW 2026.

**Q23.** In a 2-dose HPV schedule, the minimum interval between doses is

- (a) 1 month

- (b) 5 years

- (c) 2 weeks

- (d) 6 months

**Answer: (d)** — 12 months gives higher titres.

**Q24.** HPV vaccine is given

- (a) intradermally

- (b) subcutaneously in the thigh

- (c) orally

- (d) intramuscularly in the deltoid

**Answer: (d)** — MoHFW.

**Q25.** The first symptom of invasive cervical cancer is usually

- (a) pelvic pain

- (b) weight loss

- (c) leg oedema

- (d) irregular, often postcoital, bleeding

**Answer: (d)** — MSD.

**Q26.** Cervical cancer extending to the parametrium but not the pelvic wall is FIGO stage

- (a) IB

- (b) IIIB

- (c) IIB

- (d) IVA

**Answer: (c)** — MSD.

**Q27.** A woman with cervical cancer has hydronephrosis from tumour. FIGO stage:

- (a) IB2

- (b) IIA

- (c) IIIB

- (d) IA1

**Answer: (c)** — Regardless of size.

**Q28.** Cervical cancer with pelvic or para-aortic node involvement (FIGO 2018) is stage

- (a) IB

- (b) IVB only

- (c) IIIC

- (d) IIA

**Answer: (c)** — Imaging/pathology allowed.

**Q29.** Microinvasive cancer, FIGO IA1 without lymphovascular invasion, is treated by

- (a) conisation or simple hysterectomy

- (b) chemoradiation

- (c) pelvic exenteration

- (d) observation only

**Answer: (a)** — MSD.

**Q30.** Locally advanced cervical cancer is usually treated with

- (a) HPV vaccine

- (b) simple hysterectomy

- (c) cone biopsy

- (d) chemoradiation

**Answer: (d)** — Early stage: surgery.

### Active Recall

From memory: describe HPV causation and types, CIN and Bethesda terms, India's VIA screening and referral, WHO 90-70-90, India's 2026 HPV campaign (vaccine, age, dose, consent, storage, pregnancy), and cervical cancer symptoms, FIGO stage clues and treatment.
